Spectrum Vascular

Spectrum Vascular develops specialized vascular access devices aimed at mitigating complications from central line-associated bloodstream infections and catheter-related bloodstream infections, enhancing patient care in healthcare environments. Spectrum Vascular focuses on creating advanced vascular access solutions. The company is based in New York, US, and has engaged in 2 funding deals. The founder's background and previous endeavors in the industry are not disclosed.

The firm was recently acquired by Event Capital Strategies, which has enhanced its operational capabilities. Spectrum Vascular specializes in advanced vascular access devices designed to reduce complications associated with central line-associated bloodstream infections (CLABSI) and catheter-related bloodstream infections (CRBSI). Their flagship offerings include the SV Spectrum™ catheters, which are impregnated with minocycline and rifampin (M+R) to provide effective antimicrobial protection. Additionally, the company offers SV BioFlo catheters, which utilize Endexo® technology to minimize thrombus accumulation and related complications.

These products cater to hospitals, outpatient surgical centers, and healthcare providers across various regions, including North America and Europe, focusing on improving patient outcomes. Spectrum Vascular’s revenue is derived from the sale of its specialized vascular access devices, primarily through a business-to-business (B2B) model targeting hospitals and medical facilities. The transaction structure typically involves direct sales to healthcare providers, facilitated through partnerships with distributors and wholesalers within the medical device sector. The firm's flagship products, such as the SV Spectrum™ and SV BioFlo catheters, are positioned at competitive price points, reflecting their innovative technology and clinical efficacy.

Revenue generation is bolstered by the growing demand for effective infection prevention solutions within healthcare systems, as providers seek to reduce the financial burden associated with managing complications from vascular access devices. Spectrum Vascular is committed to developing new products aimed at enhancing vascular access and infection control, with plans to launch innovative solutions in the coming year. The company is targeting expansion into European markets, aiming for establishment by the end of 2024. The acquisition by Event Capital Strategies will support these initiatives by providing necessary resources and strategic direction.